Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Objective Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to invest...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 75; no. 1; pp. 84 - 97
Main Authors Prendecki, Maria, Gulati, Kavita, Pisacano, Noelle, Pinheiro, Damilola, Bhatt, Tejal, Mawhin, Marie‐Anne, Toulza, Frederic, Masuda, Esteban S., Cowburn, Andrew, Lodge, Katharine M., Tam, Frederick W. K., Roufosse, Candice, Pusey, Charles D., McAdoo, Stephen P.
Format Journal Article
LanguageEnglish
Published Boston, USA Wiley Periodicals, Inc 01.01.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN2326-5191
2326-5205
2326-5205
DOI10.1002/art.42321

Cover

Abstract Objective Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA‐induced myeloid cell activation and vasculitis pathogenesis. Methods Phosphorylation of Syk in myeloid cells from healthy controls and ANCA‐associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)–ANCA IgG activation of cells was investigated using functional assays (interleukin‐8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization. Results We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO‐ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA‐mediated cellular responses. Using targeted gene expression analysis, we identified up‐regulation of FcR‐ and Syk‐dependent signaling pathways following MPO‐ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV. Conclusion These findings indicate that Syk plays a critical role in MPO‐ANCA IgG–induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option.
AbstractList Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG-mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA-induced myeloid cell activation and vasculitis pathogenesis. Phosphorylation of Syk in myeloid cells from healthy controls and ANCA-associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)-ANCA IgG activation of cells was investigated using functional assays (interleukin-8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization. We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO-ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA-mediated cellular responses. Using targeted gene expression analysis, we identified up-regulation of FcR- and Syk-dependent signaling pathways following MPO-ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV. These findings indicate that Syk plays a critical role in MPO-ANCA IgG-induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option.
Objective Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA‐induced myeloid cell activation and vasculitis pathogenesis. Methods Phosphorylation of Syk in myeloid cells from healthy controls and ANCA‐associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)–ANCA IgG activation of cells was investigated using functional assays (interleukin‐8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization. Results We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO‐ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA‐mediated cellular responses. Using targeted gene expression analysis, we identified up‐regulation of FcR‐ and Syk‐dependent signaling pathways following MPO‐ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV. Conclusion These findings indicate that Syk plays a critical role in MPO‐ANCA IgG–induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option.
ObjectiveSyk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA‐induced myeloid cell activation and vasculitis pathogenesis.MethodsPhosphorylation of Syk in myeloid cells from healthy controls and ANCA‐associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)–ANCA IgG activation of cells was investigated using functional assays (interleukin‐8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.ResultsWe identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO‐ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA‐mediated cellular responses. Using targeted gene expression analysis, we identified up‐regulation of FcR‐ and Syk‐dependent signaling pathways following MPO‐ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.ConclusionThese findings indicate that Syk plays a critical role in MPO‐ANCA IgG–induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option.
Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG-mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA-induced myeloid cell activation and vasculitis pathogenesis.OBJECTIVESyk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG-mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA-induced myeloid cell activation and vasculitis pathogenesis.Phosphorylation of Syk in myeloid cells from healthy controls and ANCA-associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)-ANCA IgG activation of cells was investigated using functional assays (interleukin-8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.METHODSPhosphorylation of Syk in myeloid cells from healthy controls and ANCA-associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)-ANCA IgG activation of cells was investigated using functional assays (interleukin-8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO-ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA-mediated cellular responses. Using targeted gene expression analysis, we identified up-regulation of FcR- and Syk-dependent signaling pathways following MPO-ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.RESULTSWe identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO-ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA-mediated cellular responses. Using targeted gene expression analysis, we identified up-regulation of FcR- and Syk-dependent signaling pathways following MPO-ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.These findings indicate that Syk plays a critical role in MPO-ANCA IgG-induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option.CONCLUSIONThese findings indicate that Syk plays a critical role in MPO-ANCA IgG-induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option.
Author McAdoo, Stephen P.
Bhatt, Tejal
Prendecki, Maria
Tam, Frederick W. K.
Pisacano, Noelle
Masuda, Esteban S.
Mawhin, Marie‐Anne
Roufosse, Candice
Pinheiro, Damilola
Lodge, Katharine M.
Pusey, Charles D.
Gulati, Kavita
Toulza, Frederic
Cowburn, Andrew
AuthorAffiliation 1 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital London UK
2 National Heart and Lung Institute, Imperial College London UK
4 Rigel Pharmaceuticals South San Francisco California
3 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London Hammersmith Campus London UK
AuthorAffiliation_xml – name: 3 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London Hammersmith Campus London UK
– name: 4 Rigel Pharmaceuticals South San Francisco California
– name: 1 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital London UK
– name: 2 National Heart and Lung Institute, Imperial College London UK
Author_xml – sequence: 1
  givenname: Maria
  orcidid: 0000-0001-7048-7457
  surname: Prendecki
  fullname: Prendecki, Maria
  email: m.prendecki@imperial.ac.uk
  organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital
– sequence: 2
  givenname: Kavita
  orcidid: 0000-0002-2651-593X
  surname: Gulati
  fullname: Gulati, Kavita
  organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital
– sequence: 3
  givenname: Noelle
  surname: Pisacano
  fullname: Pisacano, Noelle
  organization: National Heart and Lung Institute, Imperial College
– sequence: 4
  givenname: Damilola
  surname: Pinheiro
  fullname: Pinheiro, Damilola
  organization: Centre for Inflammatory Disease, Imperial College London
– sequence: 5
  givenname: Tejal
  surname: Bhatt
  fullname: Bhatt, Tejal
  organization: Centre for Inflammatory Disease, Imperial College London
– sequence: 6
  givenname: Marie‐Anne
  surname: Mawhin
  fullname: Mawhin, Marie‐Anne
  organization: Centre for Inflammatory Disease, Imperial College London
– sequence: 7
  givenname: Frederic
  surname: Toulza
  fullname: Toulza, Frederic
  organization: Centre for Inflammatory Disease, Imperial College London
– sequence: 8
  givenname: Esteban S.
  surname: Masuda
  fullname: Masuda, Esteban S.
  organization: Rigel Pharmaceuticals
– sequence: 9
  givenname: Andrew
  surname: Cowburn
  fullname: Cowburn, Andrew
  organization: National Heart and Lung Institute, Imperial College
– sequence: 10
  givenname: Katharine M.
  surname: Lodge
  fullname: Lodge, Katharine M.
  organization: National Heart and Lung Institute, Imperial College
– sequence: 11
  givenname: Frederick W. K.
  surname: Tam
  fullname: Tam, Frederick W. K.
  organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital
– sequence: 12
  givenname: Candice
  surname: Roufosse
  fullname: Roufosse, Candice
  organization: Centre for Inflammatory Disease, Imperial College London
– sequence: 13
  givenname: Charles D.
  surname: Pusey
  fullname: Pusey, Charles D.
  organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital
– sequence: 14
  givenname: Stephen P.
  orcidid: 0000-0001-8260-8770
  surname: McAdoo
  fullname: McAdoo, Stephen P.
  organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36428281$$D View this record in MEDLINE/PubMed
BookMark eNp9kcFu1DAQhi1URMvSAy-AInGhh21tx3biE4oiCpUqIcHC1fI6TuuS2IvtFEVceAfekCdhuttWUAl8GVv-5tc_8z9Fez54i9Bzgo8JxvREx3zMaEnJI3QARSw5xXzv7k4k2UeHKV1hOLLCAvMnaL8UjNa0Jgfo-8f5S9GY7K51dsEXzheti2Ya4OkvCu27YuVSmmxx5r3OUMZx8rZo7TCkG7rxANopx7C5dEPRzjlsBp1GZ7Zf69DNv378bFIKxkF_V3zWCeRddukZetzrIdnD27pAn07frNp3y_P3b8_a5nxpOMFk2fe4FlILxqUglgtWUVxKjsveGGIFrYWu1nhtGCtLU1sjOhhNYlFhZrpKynKBXu90N9N6tJ2xPkc9qE10o46zCtqpv3-8u1QX4VrBfqWsMQeFV7cKMXydbMpqdMnACrS3YUqKVgyDIQYWFujlA_QqTNHDfEDxmmPGtpZe_Gnp3stdMAAc7QATQ0rR9vcIwTe-qILc1TZ3YE8esMblbZwwjRv-1_HNDXb-t7RqPqx2Hb8BAE2_2g
CitedBy_id crossref_primary_10_1093_rheumatology_keae566
crossref_primary_10_1186_s13075_023_03201_9
crossref_primary_10_3389_fphar_2023_1056154
crossref_primary_10_3389_fimmu_2023_1261151
crossref_primary_10_1016_j_heliyon_2023_e15625
crossref_primary_10_1016_j_imlet_2024_106933
Cites_doi 10.1016/j.bbamcr.2009.03.004
10.1681/ASN.2010050477
10.1002/path.5746
10.1016/S1074-7613(01)00150-9
10.1084/jem.20081859
10.1016/j.kint.2019.12.014
10.1093/nar/gkv007
10.1097/01.ASN.0000113241.98702.77
10.1074/jbc.RA119.008045
10.2215/CJN.11501114
10.1038/nbt.1990
10.1084/jem.186.7.1027
10.1002/1529-0131(200107)44:7<1698::AID-ART294>3.0.CO;2-J
10.1124/jpet.106.109058
10.1111/cei.12625
10.1111/imr.12455
10.1038/nri840
10.1046/j.1523-1755.1999.055003852.x
10.1056/NEJMoa0909169
10.1073/pnas.87.11.4115
10.4049/jimmunol.131.1.140
10.1016/j.immuni.2012.11.015
10.1056/NEJMoa1000500
10.1016/j.jmb.2012.11.007
10.1016/S0167-5699(99)01574-1
10.1681/ASN.V83386
10.1046/j.1523-1755.2000.057003846.x
10.1182/blood-2010-12-326355
10.1038/nri2765
10.1074/jbc.274.20.14229
10.1093/nar/gkv468
10.1016/S0021-9258(20)80545-6
10.1002/ajh.25125
10.1128/MCB.18.7.4209
10.1002/art.23757
10.1111/j.1365-2249.1994.tb06137.x
10.4049/jimmunol.153.3.1271
10.1074/jbc.M806340200
10.1681/ASN.2009030263
10.1038/ki.2015.29
10.4049/jimmunol.161.12.6909
10.1002/prp2.175
10.1074/jbc.271.18.10775
10.1681/ASN.2013090978
10.1172/JCI119662
ContentType Journal Article
Copyright 2022 The Authors. published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
2022. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 The Authors. published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
– notice: 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
– notice: 2022. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
5PM
DOI 10.1002/art.42321
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE

Toxicology Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate SYK ACTIVATION IN ANCA‐ASSOCIATED VASCULITIS
EISSN 2326-5205
EndPage 97
ExternalDocumentID PMC10099805
36428281
10_1002_art_42321
ART42321
Genre researchArticle
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Academy of Medical Sciences
  funderid: SGL023/1071
– fundername: Vasculitis UK
– fundername: ;
– fundername: ;
  grantid: SGL023/1071
GroupedDBID 0R~
1OC
24P
33P
3SF
4.4
52O
52U
52V
53G
5VS
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCUV
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
DCZOG
DIK
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
EX3
F00
FUBAC
G-S
G.N
GODZA
HGLYW
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
NF~
O66
O9-
OK1
OVD
P2W
PQQKQ
QB0
ROL
SUPJJ
SV3
TEORI
V9Y
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WVDHM
WXSBR
YCJ
AAFWJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
H94
K9.
7X8
5PM
ID FETCH-LOGICAL-c5101-ff0869a645961e56472039503fcc1e6286a7b0bc4433c8ec6d828906704cd7993
IEDL.DBID 24P
ISSN 2326-5191
2326-5205
IngestDate Thu Aug 21 18:38:16 EDT 2025
Fri Jul 11 02:49:20 EDT 2025
Fri Jul 25 12:08:15 EDT 2025
Thu Apr 03 07:06:55 EDT 2025
Tue Jul 01 00:56:06 EDT 2025
Thu Apr 24 23:02:51 EDT 2025
Wed Jan 22 16:21:36 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Attribution-NonCommercial
2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5101-ff0869a645961e56472039503fcc1e6286a7b0bc4433c8ec6d828906704cd7993
Notes Supported by the NIHR Imperial Biomedical Research Centre. Dr. Prendecki's work was supported by the Academy of Medical Sciences (grant SGL023/1071) and by an NIHR Clinical Lectureship. Dr. Tam's work was supported by the Ken and Mary Minton Chair of Renal Medicine. Dr. McAdoo's work was supported by Vasculitis UK and by an Imperial College Wellcome Trust ISSF Fellowship.
https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42321&file=art42321‐sup‐0001‐Disclosureform.pdf
Presented in abstract form at the 19th International Vasculitis and ANCA Workshop in Philadelphia, PA, in April 2019
.
Author disclosures are available at
https://doi.org/10.1093/rheumatology/kez061.027
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Author disclosures are available at https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42321&file=art42321‐sup‐0001‐Disclosureform.pdf.
Presented in abstract form at the 19th International Vasculitis and ANCA Workshop in Philadelphia, PA, in April 2019 (https://doi.org/10.1093/rheumatology/kez061.027).
ORCID 0000-0002-2651-593X
0000-0001-7048-7457
0000-0001-8260-8770
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.42321
PMID 36428281
PQID 2758504499
PQPubID 946334
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10099805
proquest_miscellaneous_2740503444
proquest_journals_2758504499
pubmed_primary_36428281
crossref_primary_10_1002_art_42321
crossref_citationtrail_10_1002_art_42321
wiley_primary_10_1002_art_42321_ART42321
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2023
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – month: 01
  year: 2023
  text: January 2023
PublicationDecade 2020
PublicationPlace Boston, USA
PublicationPlace_xml – name: Boston, USA
– name: United States
– name: Atlanta
PublicationTitle Arthritis & rheumatology (Hoboken, N.J.)
PublicationTitleAlternate Arthritis Rheumatol
PublicationYear 2023
Publisher Wiley Periodicals, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Periodicals, Inc
– name: Wiley Subscription Services, Inc
References 2010; 10
2015; 181
2011; 118
2006; 319
2015; 3
1983; 131
2000; 21
1994; 153
2013; 425
2015; 10
2008; 58
2010; 363
2002; 2
2014; 25
2001; 44
1993; 268
1993; 1
2008; 283
1997; 8
1998; 18
2010; 21
1990; 87
2013; 38
2020; 97
2021; 255
2000; 57
1997; 186
2004; 15
2015; 88
1997; 100
2015; 43
1999; 274
1996; 271
1999; 55
2018; 93
2019; 294
2009; 206
2001; 14
2011; 29
2009; 1793
2016; 273
1998; 161
1994; 98
e_1_2_7_6_1
Savage CO (e_1_2_7_13_1) 1993; 1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_42_1
e_1_2_7_43_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_10_1
e_1_2_7_46_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
Porges AJ (e_1_2_7_14_1) 1994; 153
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
Kurlander RJ (e_1_2_7_38_1) 1983; 131
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
e_1_2_7_39_1
References_xml – volume: 319
  start-page: 998
  year: 2006
  article-title: R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex‐mediated inflammation
  publication-title: J Pharmacol Exp Ther
– volume: 98
  start-page: 270
  year: 1994
  end-page: 8
  article-title: Activation of granulocytes by anti‐neutrophil cytoplasmic antibodies (ANCA): a Fc γ RII‐dependent process
  publication-title: Clin Exp Immunol
– volume: 25
  start-page: 2291
  year: 2014
  end-page: 302
  article-title: Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN
  publication-title: J Am Soc Nephrol
– volume: 21
  start-page: 1628
  year: 2010
  article-title: Histopathologic classification of ANCA‐associated glomerulonephritis
  publication-title: J Am Soc Nephrol
– volume: 186
  start-page: 1027
  year: 1997
  end-page: 39
  article-title: A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages
  publication-title: J Exp Med
– volume: 206
  start-page: 577
  year: 2009
  end-page: 93
  article-title: Critical role of phospholipase Cγ2 in integrin and Fc receptor‐mediated neutrophil functions and the effector phase of autoimmune arthritis
  publication-title: J Exp Med
– volume: 44
  start-page: 1698
  year: 2001
  end-page: 706
  article-title: Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro
  publication-title: Arthritis Rheum
– volume: 57
  start-page: 846
  year: 2000
  end-page: 62
  article-title: Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features
  publication-title: Kidney Int
– volume: 181
  start-page: 65
  year: 2015
  end-page: 75
  article-title: CD14 expression is increased on monocytes in patients with anti‐neutrophil cytoplasm antibody (ANCA)‐associated vasculitis and correlates with the expression of ANCA autoantigens
  publication-title: Clin Exp Immunol
– volume: 38
  start-page: 475
  year: 2013
  end-page: 88
  article-title: The BAFF receptor transduces survival signals by co‐opting the B cell receptor signaling pathway
  publication-title: Immunity
– volume: 153
  start-page: 1271
  year: 1994
  end-page: 80
  article-title: Anti‐neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc γ RIIa
  publication-title: J Immunol (Baltimore)
– volume: 100
  start-page: 1416
  year: 1997
  end-page: 24
  article-title: Antineutrophil cytoplasmic antibodies induce monocyte IL‐8 release. Role of surface proteinase‐3, α1‐antitrypsin, and Fcγ receptors
  publication-title: J Clin Invest
– volume: 1
  start-page: 190
  year: 1993
  end-page: 5
  article-title: Anti‐neutrophil cytoplasm antibodies can recognize vascular endothelial cell‐bound anti‐neutrophil cytoplasm antibody‐associated autoantigens
  publication-title: Exp Nephrol
– volume: 283
  start-page: 32650
  year: 2008
  end-page: 9
  article-title: Molecular mechanism of the Syk activation switch
  publication-title: J Biol Chem
– volume: 15
  start-page: 796
  year: 2004
  end-page: 808
  article-title: Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcγ receptors and CD18
  publication-title: J Am Soc Nephrol
– volume: 93
  start-page: 921
  year: 2018
  end-page: 30
  article-title: Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo‐controlled trials
  publication-title: Am J Hematol
– volume: 3
  year: 2015
  article-title: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib
  publication-title: Pharmacol Res Perspect
– volume: 14
  start-page: 693
  year: 2001
  end-page: 704
  article-title: Fc γ RIII mediates neutrophil recruitment to immune complexes. A mechanism for neutrophil accumulation in immune‐mediated inflammation
  publication-title: Immunity
– volume: 21
  start-page: 148
  year: 2000
  end-page: 54
  article-title: Tyrosine kinase Syk: essential functions for immunoreceptor signalling
  publication-title: Immunol Today
– volume: 425
  start-page: 309
  year: 2013
  end-page: 33
  article-title: Structural and biophysical characterization of the Syk activation switch
  publication-title: J Mol Biol
– volume: 97
  start-page: 1196
  year: 2020
  end-page: 207
  article-title: Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre‐clinical model
  publication-title: Kidney Int
– volume: 255
  start-page: 107
  year: 2021
  end-page: 19
  article-title: Characterisation of an enhanced preclinical model of experimental MPO‐ANCA autoimmune vasculitis
  publication-title: J Pathol
– volume: 274
  start-page: 14229
  year: 1999
  end-page: 37
  article-title: Tyrosine 319 in the interdomain B of ZAP‐70 is a binding site for the Src homology 2 domain of Lck
  publication-title: J Biol Chem
– volume: 58
  start-page: 2712
  year: 2008
  end-page: 22
  article-title: Vav/Phospholipase Cγ2–mediated control of a neutrophil‐dependent murine model of rheumatoid arthritis
  publication-title: Arthritis Rheum
– volume: 268
  start-page: 24442
  year: 1993
  end-page: 8
  article-title: Cross‐linking of Fc γ receptor I (Fc γ RI) and receptor II (Fc γ RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase
  publication-title: J Biol Chem
– volume: 88
  start-page: 52
  year: 2015
  end-page: 60
  article-title: Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression
  publication-title: Kidney Int
– volume: 1793
  start-page: 1115
  year: 2009
  end-page: 27
  article-title: Syk and pTyr'd: signaling through the B cell antigen receptor [review]
  publication-title: Biochim Biophys Acta
– volume: 43
  year: 2015
  article-title: Limma powers differential expression analyses for RNA‐sequencing and microarray studies
  publication-title: Nucleic Acids Res
– volume: 8
  start-page: 386
  year: 1997
  end-page: 94
  article-title: Crosslinking of ANCA‐antigens stimulates superoxide release by human neutrophils
  publication-title: J Am Soc Nephrol
– volume: 18
  start-page: 4209
  year: 1998
  end-page: 20
  article-title: The Syk protein tyrosine kinase is essential for Fcγ receptor signaling in macrophages and neutrophils
  publication-title: Mol Cell Biol
– volume: 2
  start-page: 476
  year: 2002
  end-page: 86
  article-title: VAV proteins as signal integrators for multi‐subunit immune‐recognition receptors [review]
  publication-title: Nat Rev Immunol
– volume: 271
  start-page: 10775
  year: 1996
  end-page: 81
  article-title: Phosphoinositide 3‐kinase and p72syk noncovalently associate with the low affinity Fc γ receptor on human platelets through an immunoreceptor tyrosine‐based activation motif. Reconstitution with synthetic phosphopeptides
  publication-title: J Biol Chem
– volume: 161
  start-page: 6909
  year: 1998
  end-page: 14
  article-title: Antineutrophil cytoplasmic antibodies preferentially engage Fc γRIIIb on human neutrophils
  publication-title: J Immunol (Baltimore)
– volume: 10
  start-page: 4
  year: 2015
  end-page: 6
  article-title: ANCAs are also antimonocyte cytoplasmic autoantibodies
  publication-title: Clin J Am Soc Nephrol
– volume: 55
  start-page: 852
  year: 1999
  end-page: 63
  article-title: Interleukin‐8: a pathogenetic role in antineutrophil cytoplasmic autoantibody‐associated glomerulonephritis
  publication-title: Kidney Int
– volume: 131
  start-page: 140
  year: 1983
  end-page: 7
  article-title: Blockade of Fc receptor‐mediated binding to U‐937 cells by murine monoclonal antibodies directed against a variety of surface antigens
  publication-title: J Immunol (Baltimore)
– volume: 294
  start-page: 7658
  year: 2019
  end-page: 68
  article-title: A reevaluation of the spleen tyrosine kinase (Syk) activation mechanism
  publication-title: J Biol Chem
– volume: 43
  start-page: W566
  year: 2015
  end-page: 70
  article-title: ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap
  publication-title: Nucleic Acids Res
– volume: 10
  start-page: 387
  year: 2010
  end-page: 402
  article-title: The Syk tyrosine kinase: a crucial player in diverse biological functions [review]
  publication-title: Nat Rev Immunol
– volume: 118
  start-page: e16
  year: 2011
  end-page: 31
  article-title: Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets
  publication-title: Blood
– volume: 363
  start-page: 211
  year: 2010
  end-page: 20
  article-title: Rituximab versus Cyclophosphamide in ANCA‐associated renal vasculitis
  publication-title: New Engl J Med
– volume: 29
  start-page: 1046
  year: 2011
  end-page: 51
  article-title: Comprehensive analysis of kinase inhibitor selectivity
  publication-title: Nat Biotech
– volume: 21
  start-page: 231
  year: 2010
  end-page: 6
  article-title: A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis
  publication-title: J Am Soc Nephrol
– volume: 273
  start-page: 121
  year: 2016
  end-page: 39
  article-title: Tyrosine kinase signaling pathways in neutrophils [review]
  publication-title: Immunol Rev
– volume: 363
  start-page: 1303
  year: 2010
  end-page: 12
  article-title: An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
  publication-title: New Engl J Med
– volume: 87
  start-page: 4115
  year: 1990
  end-page: 9
  article-title: Anti‐neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro
  publication-title: Proc Natl Acad Sci U S A
– volume: 1
  start-page: 190
  year: 1993
  ident: e_1_2_7_13_1
  article-title: Anti‐neutrophil cytoplasm antibodies can recognize vascular endothelial cell‐bound anti‐neutrophil cytoplasm antibody‐associated autoantigens
  publication-title: Exp Nephrol
– ident: e_1_2_7_5_1
  doi: 10.1016/j.bbamcr.2009.03.004
– ident: e_1_2_7_30_1
  doi: 10.1681/ASN.2010050477
– ident: e_1_2_7_47_1
  doi: 10.1002/path.5746
– ident: e_1_2_7_34_1
  doi: 10.1016/S1074-7613(01)00150-9
– ident: e_1_2_7_39_1
  doi: 10.1084/jem.20081859
– ident: e_1_2_7_22_1
  doi: 10.1016/j.kint.2019.12.014
– ident: e_1_2_7_24_1
  doi: 10.1093/nar/gkv007
– ident: e_1_2_7_19_1
  doi: 10.1097/01.ASN.0000113241.98702.77
– ident: e_1_2_7_11_1
  doi: 10.1074/jbc.RA119.008045
– ident: e_1_2_7_26_1
  doi: 10.2215/CJN.11501114
– ident: e_1_2_7_43_1
  doi: 10.1038/nbt.1990
– ident: e_1_2_7_3_1
  doi: 10.1084/jem.186.7.1027
– ident: e_1_2_7_16_1
  doi: 10.1002/1529-0131(200107)44:7<1698::AID-ART294>3.0.CO;2-J
– ident: e_1_2_7_25_1
  doi: 10.1124/jpet.106.109058
– ident: e_1_2_7_27_1
  doi: 10.1111/cei.12625
– ident: e_1_2_7_8_1
  doi: 10.1111/imr.12455
– ident: e_1_2_7_29_1
  doi: 10.1038/nri840
– ident: e_1_2_7_37_1
  doi: 10.1046/j.1523-1755.1999.055003852.x
– ident: e_1_2_7_46_1
  doi: 10.1056/NEJMoa0909169
– ident: e_1_2_7_12_1
  doi: 10.1073/pnas.87.11.4115
– volume: 131
  start-page: 140
  year: 1983
  ident: e_1_2_7_38_1
  article-title: Blockade of Fc receptor‐mediated binding to U‐937 cells by murine monoclonal antibodies directed against a variety of surface antigens
  publication-title: J Immunol (Baltimore)
  doi: 10.4049/jimmunol.131.1.140
– ident: e_1_2_7_45_1
  doi: 10.1016/j.immuni.2012.11.015
– ident: e_1_2_7_41_1
  doi: 10.1056/NEJMoa1000500
– ident: e_1_2_7_9_1
  doi: 10.1016/j.jmb.2012.11.007
– ident: e_1_2_7_7_1
  doi: 10.1016/S0167-5699(99)01574-1
– ident: e_1_2_7_35_1
  doi: 10.1681/ASN.V83386
– ident: e_1_2_7_32_1
  doi: 10.1046/j.1523-1755.2000.057003846.x
– ident: e_1_2_7_28_1
  doi: 10.1182/blood-2010-12-326355
– ident: e_1_2_7_2_1
  doi: 10.1038/nri2765
– ident: e_1_2_7_10_1
  doi: 10.1074/jbc.274.20.14229
– ident: e_1_2_7_23_1
  doi: 10.1093/nar/gkv468
– ident: e_1_2_7_33_1
  doi: 10.1016/S0021-9258(20)80545-6
– ident: e_1_2_7_42_1
  doi: 10.1002/ajh.25125
– ident: e_1_2_7_4_1
  doi: 10.1128/MCB.18.7.4209
– ident: e_1_2_7_40_1
  doi: 10.1002/art.23757
– ident: e_1_2_7_17_1
  doi: 10.1111/j.1365-2249.1994.tb06137.x
– volume: 153
  start-page: 1271
  year: 1994
  ident: e_1_2_7_14_1
  article-title: Anti‐neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc γ RIIa
  publication-title: J Immunol (Baltimore)
  doi: 10.4049/jimmunol.153.3.1271
– ident: e_1_2_7_6_1
  doi: 10.1074/jbc.M806340200
– ident: e_1_2_7_20_1
  doi: 10.1681/ASN.2009030263
– ident: e_1_2_7_31_1
  doi: 10.1038/ki.2015.29
– ident: e_1_2_7_15_1
  doi: 10.4049/jimmunol.161.12.6909
– ident: e_1_2_7_44_1
  doi: 10.1002/prp2.175
– ident: e_1_2_7_18_1
  doi: 10.1074/jbc.271.18.10775
– ident: e_1_2_7_21_1
  doi: 10.1681/ASN.2013090978
– ident: e_1_2_7_36_1
  doi: 10.1172/JCI119662
SSID ssj0000970605
Score 2.4574478
Snippet Objective Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk...
Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought...
ObjectiveSyk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 84
SubjectTerms Activation analysis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Antibodies
Antibodies, Antineutrophil Cytoplasmic
Antineutrophil cytoplasmic antibodies
Cell activation
Cytoplasm
Fc receptors
Flow cytometry
Full Length
Gene expression
Humans
Hybridization
Immune system
Immunity, Innate
Immunoglobulin G
Immunohistochemistry
Inflammation
Interleukins
Kinases
Leukocytes
Leukocytes (neutrophilic)
Monocytes
Myeloid cells
Pathogenesis
Peroxidase
Phosphorylation
Protein-tyrosine kinase
Reactive oxygen species
Receptors, Fc
Remission
Signaling
Stimulation
Syk Kinase
Syk protein
Tissues
Tyrosine
Vasculitis
Title Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.42321
https://www.ncbi.nlm.nih.gov/pubmed/36428281
https://www.proquest.com/docview/2758504499
https://www.proquest.com/docview/2740503444
https://pubmed.ncbi.nlm.nih.gov/PMC10099805
Volume 75
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2326-5205
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0000970605
  issn: 2326-5191
  databaseCode: DIK
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LTttAFB0hKqFuKlpoG0rRULHoxo0fY8cWqygUJSAqJKDKzppXiIUZR3ksom74B_6QL-m94wdEoVI3kaW5cZy5vp5zZjznEHLEgfZEPFCOiGLlMA25EJ6QjgiiSGogzsIKmF78ivo37GwYDjfIcb0XptSHaCbcsDLs8xoLnItZ-1k0FHr2B64yAvV54-Goj7LO7LKZYHETFIYJrbmcHzmAVLxaWcj12823V8ejNZC5_q7kSwxrB6HTbfKuQo-0W6b7PdnQ5gPZuqjWx3fIn6vlHe3K2rKMZob2sqm0Fl3mlnKj6LXtaTowBlAmHeD2EE17Os9nGN1F4wi9mE-LyTjLaW85LyaAr-8zaZtEoZZPD491TrWiv-2brCiMtEtuTn9e9_pOZa_gSCxEZzQCOpNwVJOJPB2ijrwbJKEbjKT0NG5Z5R3hCslYEMhYy0ghO8N9PUyqDuCaj2TTFEZ_JpRDD2sVKxEnmiVwUvT_BWKFPh5c6aRFvtednMpKexwtMPK0VE32U8hHavPRIt-a0EkpuPFa0H6dqbSquVnqI_VxGVC4FjlsmqFacAmEG10sMIahAA5jrEU-lYltfiVAKubHcPJ4JeVNACpxr7aYbGwVuT0E2rEbwv-0d8e_rzwFmmIP9v4_9At5iyb35cTPPtmcTxf6K0ChuTiwtzx8ngzO_wI4hAcA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LbtNAFL2qWgnYoJYCTV8MFQs2pn6Mp7bEJopaJdBUSKSoO8vzSGs1jKM0WURs-If-Yb-Ee8cPiAoSO0tzYztz59rnzHjOAXiXI-0ReaQ9KRLtcYO5kIFUnoyEUAaJs3QCpsML0b_kn67iqzX42OyFqfQh2gk3qgz3vKYCpwnp49-qodi1H2iZEbnPBhehT2M65F_aGRY_JWWY2LnLhcJDqBI00kJ-eNz-evWF9AhlPv5Y8k8Q695CZ5vwvIaPrFvlewvWjH0BT4b1Avk2_Pi6vGVd1XiWscKyXjFTzqPLXrPcajZyXc0G1iLMZAPaH2JYz0wmdxTdJecIs5jPyulNMWG95bycIsD-XijXJEu9fPh53yTVaPbNfcpKykgv4fLsdNTre7W_gqeoEr3xGPlMmpOcjAhMTELyfpTGfjRWKjC0ZzU_kb5UnEeRSowSmugZbezhSp8gsHkF67a0ZgdYjj1sdKJlkhqe4knJABiZFRl55NqkHXjfdHKmavFx8sCYZJVscphhPjKXjw4ctaHTSnHjb0H7TaayuujuspC4j8-Rw3XgbduM5UJrILk15YJiOCngcM478LpKbHuViLhYmODJk5WUtwEkxb3aYosbJ8kdENJO_Bj_pxsd_77zDHmKO9j9_9A38LQ_Gp5n54OLz3vwjBzvq1mgfVifzxbmAHHRXB664f8LOV8Jdg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LTttAFL1CICE2qDybQssUdcHG4MfY2GIVBSLSFoRUQOwszyNgEcZRSBZRN_0H_rBf0nvHD4igEjtLc_2a62ufM-M5B-BbhrQnygLliChWDteYC-EJ6YggiqRG4iysgOnZeXR6xb_fhDdzcFSvhSn1IZoBN6oM-76mAh-q_sGzaCj27D7NMiL1WeAk2UKyzvyiGWBxExKGCa25nB85iFS8WlnI9Q-avWe_R69A5ut_JV9iWPsR6n6A5Qo9snaZ7hWY02YVFs-q-fE1-P1res_asrYsY7lhnXwkrUWXuWWZUezS9jTrGYMok_VoeYhmHT0YPFJ0m4wj9GQ8KoZ3-YB1puNiiPj6IZe2SRRq-vfPU51Trdi1_ZOVhJHW4ap7ctk5dSp7BUdSITr9PtKZJCM1mcjTIenIu0ESukFfSk_TktXsULhCch4EMtYyUsTOaF0Pl-oQcc0GzJvC6I_AMuxhrWIl4kTzBA9K_r9IrMjHI1M6acFe3cmprLTHyQJjkJaqyX6K-UhtPlqw24QOS8GNt4K260ylVc09pj5RH5cjhWvB16YZq4WmQDKjiwnFcBLA4Zy3YLNMbHOWgKiYH-PB45mUNwGkxD3bYvI7q8jtEdCO3RDv0z4d_7_yFGmK3fj0_tAdWLw47qY_e-c_tmCJ_O7LMaBtmB-PJvozoqKx-GKf_n-orAio
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Syk+Activation+in+Circulating+and+Tissue+Innate+Immune+Cells+in+Antineutrophil+Cytoplasmic+Antibody-Associated+Vasculitis&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Prendecki%2C+Maria&rft.au=Gulati%2C+Kavita&rft.au=Pisacano%2C+Noelle&rft.au=Pinheiro%2C+Damilola&rft.date=2023-01-01&rft.eissn=2326-5205&rft.volume=75&rft.issue=1&rft.spage=84&rft_id=info:doi/10.1002%2Fart.42321&rft_id=info%3Apmid%2F36428281&rft.externalDocID=36428281
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon